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a recent widely publicised Lancet review of statin efficacy and safety data generated more controversy than it resolved.1 Led by Professor Rory Collins of Oxford University, the review 
claimed that the benefits of statins have been underestimated 
and the risks exaggerated. Claims of statin intolerance in up to 
20% of patients, the review argues, are not supported by large-
scale evidence from randomised trials. In fact, Collins et al. 
claim that statin therapy is no less well tolerated than placebo.
Collins further claimed that the controversy about statin 
intolerance and myopathy rates emerged only in the past 2 or 
3 years as manufacturers began marketing newer and “very 
expensive” cholesterol-lowering agents, such as, proprotein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitors for 
patients classified as statin intolerant. He also pointed out that 
industry has funded reports on statin intolerance, as in the 
case of the European Atherosclerosis Society’s report2 which, 
not only had funding from makers of PCSK9 inhibitors, but 
also had its meetings coordinated by a commercial entity 
funded by the manufacturers.
Collins claimed that one could 
expect that 5 years of a statin regimen 
that lowered LDL cholesterol by 
2mmol/L would prevent major 
vascular events in about 1000 of 
10,000 secondary-prevention 
patients and about 500 of 
10,000 primary-prevention 
patients, with a bigger 
benefit to be expected 
with lifelong statin use. 
Moreover, he added, 
whereas many of 
the adverse effects (such as myopathy) can be reversed with no 
residual ill-effects by stopping the statin, the effects of a heart 
attack or stroke are often irreversible.
Dr Harlan Krumholz (Yale University), commenting on the 
review in the BMJ,3 said that while the findings strongly support 
the benefits of statins in comparison to modest risks, there is 
little consideration of the limitations of the trial evidence, most 
notably a lack of robust data on elderly patients, individual trials 
whose design prevented detection of many relevant harms, and 
inconsistent methods for adverse event data collection.
A vocal critic of the review, and an author of one of the 
2013 BMJ papers,4 Dr Aseem Malhotra (Lister Hospital, 
Stevenage, UK) claims that the Clinical Trials Service Unit at 
Oxford has received hundreds of millions of pounds in funding 
from statin manufacturers and that Collin’s group has not 
released raw data on the major statin randomised controlled 
trials for independent scrutiny. He adds that by using 
predominantly industry-sponsored trials designed for the 
purpose of determining the benefits of statins but minimising 
side-effects, this review simply adds false precision to 
biased estimates. He also noted that Pfizer’s own patient 
leaflet on atorvastatin states that common side-effects 
possibly affecting up to one in 10 people include 
sore throat, nausea, digestive problems, muscle and 
joint pains. 
Malhotra has also co-authored a recent 
systematic review revealing that in those 
patients over age 60, LDL-
cholesterol is not associated 
with cardiovascular 
disease and is 
inversely correlated 
19Volume 15, 2016  issue 06
with all-cause mortality.5 He is quick to admit that statins have 
a benefit, but adds that focusing on LDL lowering as if this was 
the end in itself is counterproductive, especially when insulin 
resistance is a more important risk factor for myocardial 
infarction. He concludes that in his view, the Lancet review is 
a total whitewash, and agrees with the BMJ’s editor-in-chief, 
Fiona Godlee, who described it as “the trialists making their 
own homework”.  
It turns out that Godlee and Collins have been at odds 
ever since Collins called on the BMJ to correct and ultimately 
withdraw the two 2013 studies that repeated claims made in a 
paper by Abramson et al.6 that side-effects of statins occur in 18% 
to 20% of people. The BMJ corrected the statements in the two 
studies, but Godlee passed the decision, on whether to retract, on 
to an independent expert panel, which rejected Collins’s request 
for retraction in June 2014. In October 2014, Collins and other co-
authors of the new Lancet review, sent a letter of complaint about 
the BMJ’s handling of the two papers to the UK’s Committee on 
Publication Ethics (COPE). In April 2016, COPE determined that 
the BMJ acted with due diligence and in line with the expectations 
under the COPE Code of Conduct.
The Lancet editor-in-chief Dr Richard Horton, however, in 
a comment accompanying the statin review,7 calls into question 
the independence of the BMJ-appointed panel’s judgement, 
noting that the chair had previously written critically about 
statin use among older patients. Horton observed that more 
than 200,000 patients were estimated to have stopped taking a 
statin in the 6 months after adverse media coverage following 
publication of the disputed research, and drew parallels 
between “this statin scare” and the MMR vaccine scare that 
began with a now-retracted research paper that had led to 
widespread vaccine hesitancy. 
Horton’s comment about COPE’s conduct prompted Godlee’s 
rapid response letter8 of 14th September 2016, that COPE did not 
decline to act but deliberated on the concerns raised by Collins 
et al., and on the BMJ’s response, and came to a clear conclusion 
that the BMJ had acted appropriately. Godlee has also written 
to England’s chief medical officer asking for an inquiry into the 
statins saga and for an independent review of the evidence on 
statins. She claims that an independent third-party scrutiny of the 
statins trial data remains an essential next step if this increasingly 
bitter and unproductive dispute is to be resolved.
taKE homE mEssagEs
 1. Apart from the above claims of drug-company funding and 
dubious research quality, the Lancet review in question, 
penned by several professors of medicine and cardiology, 
is flawed for at least another two reasons. One is the fact 
that all the data is based on routine LDL measurements. 
Previous instalments in this Synapse series have put 
forward evidence for LDL having two biologically different 
sub-fractions – a large light particle LDL and a small 
dense particle LDL – with only the latter being related to 
atherosclerosis. Routine LDL measurements do not indicate 
whether moderately raised LDL is due to a raised large or 
small sub-fraction. The surrogate marker for a raised small 
LDL sub-fraction is raised triglyceride (TRG) combined 
with low HDL – the higher the TRG/HDL ratio, the 
higher the risk for atherosclerotic disease. 
2. Another flaw in the review is the persistent belief that the 
benefit of statins is via their blood lipid–lowering action. It 
is now well-established that the essence of atherosclerosis 
is an inflammatory disease of arteries. Statins are now 
recognised to be potent anti-inflammatory-cytokine 
agents, and their clinical benefit is mainly via this anti-
inflammatory route. The high-sensitivity C-reactive protein 
(HsCRP) is the other valuable measurement of possible 
atherosclerotic inflammatory activity, particularly when 
combined with the TRG/HDL ratio.
3. As pointed out above by Dr Aseem Malhotra, insulin 
resistance (chronic hyperinsulinaemia) is a more potent 
indicator of myocardial infarction risk than LDL. This has 
been highlighted in a previous instalment of this Synapse 
series, which also pointed out that the TRG/HDL ratio is a 
surrogate marker for insulin-resistance/hyperinsulinaemia. 
Some private laboratories in Malta will be adopting the 
TRG/HDL ratio and the HsCRP as the main markers of 
atherosclerotic activity risk. 
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